Working… Menu

DNA Chip Based Prognosis of Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00973427
Recruitment Status : Completed
First Posted : September 9, 2009
Last Update Posted : September 23, 2015
Information provided by (Responsible Party):
Medical Prognosis Institute A/S

Brief Summary:
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Condition or disease
Carcinoma, Non-Small-Cell Lung

Layout table for study information
Study Type : Observational
Actual Enrollment : 144 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: DNA Chip Based Prognosis of Lung Cancer
Study Start Date : June 2008
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Disease-related survival [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Time to progression [ Time Frame: 5 years ]

Biospecimen Retention:   Samples Without DNA
post resection specimen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The population consist of subjects being examined for NSCLC at Roswell Park Cancer Institute (US), University of Alabama (US), Copenhagen University (DK), Odense University Hospital (DK) and Aarhus University Hospital (DK)

Inclusion Criteria:

  1. A histological diagnosis of primary NSCLC stage Ia
  2. Surgical removal of the tumor
  3. Age between 18 and 75 years
  4. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
  2. Adjuvant treatment with chemotherapy.
  3. Prior history of cancer in the past 5 years or breast cancer at any time.
  4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00973427

Layout table for location information
United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35294
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Aarhus University Hospital
Aarhus, Denmark, 8200
University of Copenhagen
Copenhagen, Denmark, 2100
Odense University Hospital
Odense, Denmark, 5000
Sponsors and Collaborators
Medical Prognosis Institute A/S
Layout table for investigator information
Study Chair: Steen Knudsen, PhD Medical Prognosis Institute (MPI)
Study Director: Jens B. Sørensen, MD Dept. Oncology, Copenhagen University
Study Director: Jesper Ravn, MD University of Copenhagen
Layout table for additonal information
Responsible Party: Medical Prognosis Institute A/S Identifier: NCT00973427    
Other Study ID Numbers: MPI-1001
WIRB Protocol #20080904
First Posted: September 9, 2009    Key Record Dates
Last Update Posted: September 23, 2015
Last Verified: September 2015
Keywords provided by Medical Prognosis Institute A/S:
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases